Abstract
Background and Aims Sedation endoscopy using propofol significantly reduces procedure-related discomforts and increases patient compliance. However, propofol has a very narrow therapeutic window, and the dose required for each individual is very diverse; hence, it must be used with extreme caution. Maintaining an appropriate dosing interval is also important to administer the appropriate dose. This study aimed to investigate the change in propofol dose before and after stopwatch installation in the endoscopy unit and to assess the effect of administration intervals on propofol usage patterns.
Methods This retrospective study included people who underwent sedation endoscopy without biopsies between January 1 and October 31 of 2019. The participants were divided into before (n = 526) and after (n = 845) groups. In the after group, drug interval was rigorously maintained using the stopwatch. Changes in propofol dose with respect to sex, age, weight, height, and endoscopic procedure time were statistically analyzed. Group difference between each variable was reduced by propensity score matching adjustment, and statistical analysis was conducted using the R program.
Results No adverse event occurred. The propofol dosage per body weight decreased from 1.38 mg/kg (before) to 1.27 mg/kg (after) in females (p < 0.0001), while it increased from 1.23 mg/kg to 1.28 mg/kg in males (p = 0.016). These changes were found to be significantly different between sexes before the installation of the stopwatch (p < 0.0001). However, after the installation of the stopwatch, there was no significant difference in propofol dosage between males and females (1.28 mg/kg vs. 1.27 mg/kg; p = 0.9752).
Conclusions The use of a stopwatch in sedative upper gastrointestinal endoscopy reduced the propofol requirement in females but not in males.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Public Institutional Review Board designated by South Korea Ministry of Health and Welfare gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
